DefinitionThis section has been translated automatically.
Selective cyclooxygenase inhibitor (COX-2 inhibitor). Active metabolite of parecoxib.
IndicationThis section has been translated automatically.
Symptomatic treatment of osteoarthrosis or rheumatoid arthritis. Treatment of primary dysmenorrhoea.
You might also be interested in
Pregnancy/nursing periodThis section has been translated automatically.
Contraindicated in the 3rd trimester (risk of weakness in labour and premature closure of the Botalli duct). Strictest examination of the indication in the 1st and 2nd trimester (insufficient data, no adequate and well-controlled studies available!) Do not use in the lactation period!
Dosage and method of useThis section has been translated automatically.
- Osteoarthrosis or rheumatoid arthritis: 10 mg once/day, if necessary 20 mg/day p.o. Maximum recommended daily dose: 20 mg.
- Primary dysmenorrhea: once/day 40 mg p.o. An additional 40 mg dose may be given on the first day of treatment, followed by a maximum recommended daily dose of 40 mg.
Remember! Dose adjustment is necessary in older patients (≥ 65 yrs.), especially those with a weight < 50 kg KG and with liver dysfunction!
InteractionsThis section has been translated automatically.
Fluconazole, ketoconazole, phenytoin, carbamazepine, dexamethasone, rifamycin, flecainide, propafenone, metoprolol
ContraindicationThis section has been translated automatically.
Cave!
Sulfamide allergy! Adverse drug reaction after ingestion of acetylsalicylic acid, COX-2 inhibitors or other NSAIDs, active peptic ulcers, gastrointestinal bleeding, inflammatory bowel disease, severe decompensated heart failure, severe liver dysfunction.Notice! Do not use on children!
PreparationsThis section has been translated automatically.
Bextra
Note(s)This section has been translated automatically.
Cave! The distribution of the active ingredient valdecoxib was suspended by the manufacturer Pfizer in April 2005 on recommendation of the FDA due to the danger of severe allergic skin reactions!
LiteratureThis section has been translated automatically.
- New recommendations to modernize drug manufacturing. FDA Consumption 41: 4
- Capone ML et al (2003) Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol Pharmacol 16(2 Suppl): 49-58
- Chavez ML et al (2003) Valdecoxib: a review. Clin Ther 25: 817-851
- by Scheele B et al (2003) Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial. Rheumatology (Oxford) 42 (Suppl 3): 53-59
Prof. Dr. med. Peter Altmeyer